Zura Bio Limited filed a Form 8-K with the U.S. Securities and Exchange Commission on August 17, 2026, disclosing an updated corporate presentation intended for use at upcoming conferences and investor meetings.

Key Highlights

  • Regulation FD disclosure: Zura Bio furnished an updated corporate presentation dated August 17, 2026, as Exhibit 99.1 to the filing.
  • Intended use: According to the filing, the presentation "may be used in connection with upcoming presentations at conferences and investor meetings."
  • Public access: The company disclosed that the presentation may also be accessed through the "News & Events" section of its website at investors.zurabio.com.
  • Not deemed "filed": The filing states that the information furnished under Item 7.01 "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934."
  • Signatory: The report was signed by Kim Davis, Chief Operating Officer, Chief Legal Officer and Corporate Secretary.

Zura Bio Furnishes Updated Investor Presentation Under Regulation FD

Zura Bio Limited (NASDAQ:ZURA), a Cayman Islands-incorporated company headquartered in Henderson, Nevada, submitted a current report on August 17, 2026, under Item 7.01 (Regulation FD Disclosure). The filing states that the company provided an updated corporate presentation for potential use at conferences and investor meetings, with the full presentation filed as Exhibit 99.1 and incorporated by reference into the report.

According to the filing, the presentation is also available through the "News & Events" section of the company's investor relations website. The company noted that the information furnished under Item 7.01, including Exhibit 99.1, "shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such a filing."

The company is classified as an emerging growth company as defined under Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Securities Exchange Act of 1934, according to the filing. Zura Bio's Class A Ordinary Shares, par value $0.0001 per share, are registered on The Nasdaq Stock Market under the trading symbol ZURA.

What Was Disclosed

Zura Bio Limited filed an 8-K on August 17, 2026, furnishing an updated corporate presentation under Regulation FD for use at upcoming conferences and investor meetings, accessible via the company's investor relations website.